EYSINS, Switzerland, Feb. 10, 2025 /PRNewswire/ — AliveDx announces it has submitted 510(k) premarket notification to the U.S. Food and Drug Administration (FDA) for the MosaiQ AiPlex ® Celiac Disease ...
EYSINS, Switzerland, April 3, 2025 /PRNewswire/ --Today, AliveDx announces it has submitted 510(k) premarket notification to the U.S. Food and Drug Administration (FDA) for the MosaiQ AiPlex ® ...
EYSINS, Switzerland, Feb. 3, 2025 /PRNewswire/ -- AliveDx announces the receipt of IVDR-CE mark for its MosaiQ AiPlex ® CTDplus multiplex assay. The multiplex assay enables a syndromic approach, ...
The MosaiQ solution is a next-generation IVD solution for autoimmune diseases, allergies and beyond. The multiplexed, fully automated planar microarray platform enables syndromic testing for complex ...
PathogenDx's breakthrough technology shifts the pathogen detection paradigm from microbial to molecular testing through its microarray assays, namely DetectX, EnviroX, and QuantX SANTA CLARA, ...
As sequencing projects of microbial organisms are being completed, a large number of genes of potential biological and medical relevance are classified as 'unknown' because their unique sequence and ...
Reversible phosphorylation of proteins by kinases and phosphatases represents a common molecular mechanism by which intracellular signals are transmitted. With over 2,000 human genes predicted to code ...
A tutorial session held by Dr. Robinson and Dr. Haab [17] provided more details on the technical aspects of the protein microarrays they are developing. In principle, chips can be considered "capture ...
All reagents and multiplex microarray magazines are equipped with RFID tags to save time while avoiding manual errors. Unique combination of tests The MosaiQ AiPlex CTDplus assay enables a syndromic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback